#APRE Aprea Therapeutics, Phase 2 Dosing Update:
www.globenewswire.com/news-release...
#combinationtherapies.
www.globenewswire.com/news-release...
#combinationtherapies.
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation studyFurther ATRN-119 monotherapy enrollment paused...
www.globenewswire.com
October 15, 2025 at 12:58 PM
#APRE Aprea Therapeutics, Phase 2 Dosing Update:
www.globenewswire.com/news-release...
#combinationtherapies.
www.globenewswire.com/news-release...
#combinationtherapies.
#ComboConnect by More Than Access & ISPOR Rome highlights the need for clearer #EMA guidance and better policies to support access to 149 approved #combinationtherapies in Italy, improving efficacy and adherence👉 www.cresp.it/vantaggi-e-s...
Vantaggi e sfide delle terapie combinate: ottimizzare l'accesso e la sostenibilità - CRESP
Quali sono i vantaggi delle terapie combinate, che utilizzano due o più principi attivi con meccanismi d’azione diversi? Le evidenze cliniche mostrano sempre più l’importanza di associare diversi farm...
www.cresp.it
April 29, 2025 at 2:33 PM
#ComboConnect by More Than Access & ISPOR Rome highlights the need for clearer #EMA guidance and better policies to support access to 149 approved #combinationtherapies in Italy, improving efficacy and adherence👉 www.cresp.it/vantaggi-e-s...
This review highlights the multifaceted role of YAP1 within the #TumorMicroenvironment and emphasizes advances in YAP1 inhibitors and their #translational promise in #CombinationTherapies. #medsky
To read: doi.org/10.1007/s115...
To read: doi.org/10.1007/s115...
June 29, 2026 at 1:15 PM
This review highlights the multifaceted role of YAP1 within the #TumorMicroenvironment and emphasizes advances in YAP1 inhibitors and their #translational promise in #CombinationTherapies. #medsky
To read: doi.org/10.1007/s115...
To read: doi.org/10.1007/s115...
This review highlights the multifaceted role of #YAP1 in the #TumorMicroenvironment, where it orchestrates #CancerGrowth, #Stemness, #DrugResistance, and #Metastasis, and highlights advances in YAP1 inhibitors and #CombinationTherapies. #medsky
To read: doi.org/10.1007/s115...
To read: doi.org/10.1007/s115...
May 15, 2026 at 2:00 AM
This review highlights the multifaceted role of #YAP1 in the #TumorMicroenvironment, where it orchestrates #CancerGrowth, #Stemness, #DrugResistance, and #Metastasis, and highlights advances in YAP1 inhibitors and #CombinationTherapies. #medsky
To read: doi.org/10.1007/s115...
To read: doi.org/10.1007/s115...
#oncology #precisionmedicines #cancer #cancers #MosaicTherapeutics #Astex #AstexPharmaceuticals #inlicensing #oncologyprogrammes #clinicalstageoncologyprogrammes #combinationtherapies #biomarkers #drugdiscoveryplatform #clinicaltrials
pharmatimes.com/news/mosaic-...
pharmatimes.com/news/mosaic-...
Mosaic therapeutics expands pipeline with Astex deal - PharmaTimes
Cambridge firm in-licenses two oncology programmes
pharmatimes.com
May 6, 2025 at 2:33 PM